Biography

Alexandre Mercier, PhD is a Principal Scientist in the Discovery Virology group at Gilead Sciences, where he leads a research team focused on antiviral drug discovery. Dr. Mercier received his PhD in Biochemistry from Université de Sherbrooke (Québec, Canada), followed by postdoctoral training at the University of California, San Francisco and at Novartis under the mentorship of Dr. Don Ganem. His postdoctoral research examined the epigenetic and transcriptional mechanisms governing Kaposi’s sarcoma–associated herpesvirus (KSHV) latency. Prior to joining Gilead, Dr. Mercier worked at Assembly Biosciences, contributing to the discovery of hepatitis B virus (HBV) capsid assembly modulators. At Gilead, his work centres on leading antiviral discovery efforts for the treatment of herpesvirus infections, integrating mechanistic virology with drug discovery approaches.